U.S. reproductive health companies are keen to venture into the 'huge and very underserved' Assisted Reproductive Technology (A.R.T.) market in China whose infertile population will reach 40 million by 2020.
The Society of Assisted Reproductive Technology (S.A.R.T.) has already partnered with the Chinese Medical Doctor Association (C.M.D.A.) in an initiative to advance the standards of practice of A.R.T. and related services in China.
'Hainan Boao Lecheng International Medical Tourism Pilot Zone, the first of its kind in China, is the best place for the potential collaboration and communication between Chinese and U.S. medical institutions in the field of reproductive health', said Dr. Bo Hu, chairman of the C.M.D.A. Health Management, and Health Insurance Professional committee, chairman of the Ciming Boao International Hospital.
Boao Lecheng pilot zone is a demonstration project for China's healthcare reform. It enjoys nine special preferential policies, such as special permission for importing medical technology, medical equipment and medicine, under which foreign companies will be able to set up medical organisations and foreign medications can enjoy a special import tariff.
The pilot zone, six kilometres from the site of the Boao Forum for Asia, covers an area of 20 square kilometres and is expected to be completed in five years. About 27 projects have been completed or are under construction.
Source: China Daily
No comments:
Post a Comment